Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Moderna (NasdaqGS:MRNA) Up 11% Despite Patent Lawsuit Challenges [Yahoo! Finance]Yahoo! Finance
- Arbutus Biopharma Co. (NASDAQ: ABUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction [Yahoo! Finance]Yahoo! Finance
- Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaGlobeNewswire
ABUS
Earnings
- 11/6/24 - Miss
ABUS
Analyst Actions
- 1/21/25 - HC Wainwright
ABUS
Sec Filings
- 3/24/25 - Form 144
- 3/20/25 - Form 4
- 3/20/25 - Form 4
- ABUS's page on the SEC website